Last reviewed · How we verify
BR1400-A
BR1400-A is a small molecule that targets the renin-angiotensin system.
BR1400-A is a small molecule that targets the renin-angiotensin system. Used for Hypertension.
At a glance
| Generic name | BR1400-A |
|---|---|
| Also known as | Placebo |
| Sponsor | Boryung Pharmaceutical Co., Ltd |
| Drug class | Angiotensin II receptor antagonist |
| Target | AT1 receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 2 |
Mechanism of action
BR1400-A works by inhibiting the angiotensin II receptor type 1, which plays a key role in blood pressure regulation and electrolyte balance. This mechanism is expected to lead to a reduction in blood pressure and potentially provide renoprotective effects.
Approved indications
- Hypertension
Common side effects
- Headache
- Dizziness
- Fatigue
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |